Successful treatment of Staphylococcus epidermidis prosthetic valve endocarditis with linezolid after failure of treatment with oxacillin, gentamicin, rifampicin, vancomycin, and fusidic acid regimens

References

• Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999;347:493–501.
   Google Scholar
• Aucken HM, Warner M, Ganner M, Johnson AP, Richardson JF, Cookson BD, Livermore DM. Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 2000;46:639–40.
   PubMedGoogle Scholar
• Guerin F, Buu-Hoi A, Mainardi JL, Kac G, Colardelle N, Vaupre S, et al. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. J Clin Microbiol 2000;38:2985–8.
   PubMedGoogle Scholar
• The Centers for Disease Control. Staphylococcus aureus resistant to vancomycin: United States, 2002. Jama 2002;288:824–5.
   PubMedGoogle Scholar
• The Centers for Disease Control and Prevention. Vancomycin resistant Staphylococcus aureus:Pennsylvania, 2002. Jama 2002;288:2116.
   PubMedGoogle Scholar
• Livermore DM. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J Antimicrob Chemother 2000;46:347–50.
   PubMed Web of Science ®Google Scholar
• Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233–9.
   Google Scholar
• Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiological and clinical observations as guides to therapy. Ann Intern Med 1983;98:447–55.
   Google Scholar
• Whitener C, Caputo GM, Weitekamp MR, Karchmer AW. Endocarditis due to coagulase-negative staphylococci. Microbiological, epidemiological, and clinical considerations. Infect Dis Clin North Am 1993;7:81–96.
   Google Scholar
• Karchmer AW. Prosthetic valve endocarditis: a continuing challenge for infection control. J Hosp Infect 1991;18(Suppl A):355–66.
   Google Scholar
• Brickner SJ, Hutchinson DK, Barbachyn MR, Manninen PR, Ulanowicz DA, Garmon SA, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J Med Chem 1996;39:673–9.
   PubMed Web of Science ®Google Scholar
• Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42:3251–5.
   PubMed Web of Science ®Google Scholar
• Kloss P, Xiong L, Shinabarger DL, Mankin AS. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase centre. J Mol Biol 1999;294:93–101.
   PubMed Web of Science ®Google Scholar
• Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J Antimicrob Chemother 2000;46:931–40.
   PubMed Web of Science ®Google Scholar
• Gemmell CG. Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J Antimicrob Chemother 2001;48:47–52.
   PubMed Web of Science ®Google Scholar
• Jones RN, Ballow CH, Biedenbach DJ. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagn Microbiol Infect Dis 2001;40:59–66.
   Google Scholar
• Cercenado E, Garcia-Garrote F, Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J Antimicrob Chemother 2001;47:77–81.
   PubMed Web of Science ®Google Scholar
• Fang CT, Chang SC, Chen YC, Hsieh SM, Hsieh WC. In vitro activity of linezolid against clinical Gram-positive bacterial isolates from Taiwan: an area with a high prevalence of antibiotic resistance. Int J Antimicrob Agents 2001;18:267–70.
   Google Scholar
• Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid vs vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481–90.
   PubMed Web of Science ®Google Scholar
• Andrade-Baiocchi S, Tognim MC, Baiocchi OC, Sader HS. Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization. Diagn Microbiol Infect Dis 2003;45:149–52.
   Google Scholar
• San Pedro GS, Cammarata SK, Oliphant TH, Todisco T. Linezolid vs ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 2002;34:720–8.
   PubMed Web of Science ®Google Scholar
• Till M, Wixson RL, Pertel PE. Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002;34:1412–4.
   PubMed Web of Science ®Google Scholar
• Ford CW, Hamel JC, Stapert D, Moerman JK, Hutchinson DK, Barbachyn MR, Zurenko GE. Oxazolidinones: new antibacterial agents. Trends Microbiol 1997;5:196–200.
   Google Scholar
• Patel R, Rouse MS, Piper KE, Steckelberg JM. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1999;34:119–22.
   PubMed Web of Science ®Google Scholar
• Wilcox MH. Efficacy of linezolid vs comparator therapies in Gram-positive infections. J Antimicrob Chemother 2003;51(Suppl 2):I27–35.
   PubMedGoogle Scholar
• Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use programme. Clin Infect Dis 2003;36:159–68.
   PubMed Web of Science ®Google Scholar
• John MA, Pletch C, Hussain Z. In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci. J Antimicrob Chemother 2002;50: 933–8.
   Google Scholar
• Jacqueline C, Caillon J, Le Mabecque V, Miegeville AF, Donnio PY, Bugnon D, Potel G. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003;51:857–64.
   Google Scholar
• MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003;51(Suppl 2):17–25.
   Google Scholar
• Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, et al. Worldwide assessment of line- zolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003;47:1824–31.
   PubMed Web of Science ®Google Scholar
• Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 2004;64:1621–42.
   PubMed Web of Science ®Google Scholar